Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 21379 participants.

Also called NCT01225562

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 21,379 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01225562
  • EudraCT 2009-017242-30
Other papers using this trial's data
  • Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial Journal of the American Heart Association, 2020-05-18 DOI, PubMed 32410485, PMC7660882 In the PMC Open Access subset under CC BY-NC-ND.
  • Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status Thrombosis and haemostasis, 2017-05-03 DOI, PubMed 28300867
  • Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial Journal of the American College of Cardiology, 2017-08-01 DOI, PubMed 28750695
  • Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54 Journal of the American College of Cardiology, 2017-09-12 DOI, PubMed 28882235
  • Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 European heart journal, 2016-04-07 DOI, PubMed 26491109
  • Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial Journal of the American Heart Association, 2021-09-07 DOI, PubMed 34423649, PMC8649257 In the PMC Open Access subset under CC BY-NC-ND.
  • Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial JAMA cardiology, 2016-07-01 DOI, PubMed 27438319
  • Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54 European heart journal, 2020-05-01 DOI, PubMed 31811715
  • Long-term use of ticagrelor in patients with prior myocardial infarction The New England journal of medicine, 2015-05-07 DOI, PubMed 25773268
  • Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction Journal of the American Heart Association, 2021-02-16 DOI, PubMed 33559485, PMC7955333 In the PMC Open Access subset under CC BY-NC.
  • Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) Circulation, 2016-09-20 DOI, PubMed 27576775
  • Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54 Journal of the American College of Cardiology, 2016-06-14 DOI, PubMed 27046160
  • Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54 Journal of the American Heart Association, 2018-11-20 DOI, PubMed 30571502, PMC6404436 In the PMC Open Access subset under CC BY-NC-ND.
  • Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease Journal of the American College of Cardiology, 2016-06-14 DOI, PubMed 27046162
  • Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease Journal of the American College of Cardiology, 2018-02-06 DOI, PubMed 29406853

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01225562. Randomized; quadruple masking; primary purpose prevention. Start 2010-10 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2015-12-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Acronym
PEGASUS
Condition
Cardiovascular Death
Condition
Atherothrombosis
Condition
Stroke
Intervention (Drug)
Ticagrelor 90 mg
Intervention (Drug)
Ticagrelor 60 mg
Intervention (Drug)
Ticagrelor Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01225562
Content hash
25d919de0a35019dcaf72aaefdc9faa1b933433e5a0302c2a96a51ed62276d67